Ray Gervacio Blanco, MD
Surgical Oncology · Baltimore, MDNPI 1891773966
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 21 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Johnson & Johnson at 46.1% of the total. 2025 is the largest year on record at $241, more than ten times the $14 reported in 2019.
Across 21 payments — averaging $23.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$231
- Medtronic$65
- Merck$51
- Hologic Sales And Service, LLC$45
- GE HealthCare$30
- Baxter Healthcare$23
- plus $57 from 3 others
What the payments were for
- Food & beverage$502100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 9 | $231 |
| Medtronic | 1 | $65 |
| Merck | 3 | $51 |
| Hologic Sales And Service, LLC | 1 | $45 |
| GE HealthCare | 3 | $30 |
| Baxter Healthcare | 1 | $23 |
| Acera Surgical, Inc. | 1 | $22 |
| Organogenesis Inc. | 1 | $20 |
| Axogen | 1 | $15 |
How this compares
$502 in reported general payments places this provider in the 60th percentile of 40 surgical oncology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nystatin | 11 | $362 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 22 | $198 |
| Famotidine | 11 | $187 |
Paid to pharmacies, not to this prescriber.
Other surgical oncology in Baltimore
- Kerri LopezBaltimore$16K
- Rebecca BrownBaltimore$13K
- Arun MavanurBaltimore$4K
- Armando SardiBaltimore$2K
- Lisa JacobsBaltimore$2K
- Daria AbolghasemiBaltimore$2K
- Richelle WilliamsBaltimore$2K
- Humair QuadriBaltimore$1K
- Kelly LafaroBaltimore$945
- Jeremy DavisBaltimore$376
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.